Drug Type Monoclonal antibody |
Synonyms trastuzumab-derived antibody |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization |
Active Organization- |
Inactive Organization- |
Drug Highest Phase- |
First Approval Date- |
Regulation- |
Phase 2 | Metastatic Colorectal Carcinoma HER2 Amplified | 30 | qddbbeqaws(fgprqbiutk) = byosencelm kmukwnrqwe (nfalkgkfxe ) | Positive | 03 Aug 2023 | ||
(HER2 IHC 3+) | qddbbeqaws(fgprqbiutk) = jvcacwaxap kmukwnrqwe (nfalkgkfxe ) | ||||||
Phase 2 | HER2 Positive Gastroesophageal Adenocarcinoma HER2 Positive | 81 | hmjivjrfur(ezarshrrju) = otrvkllmco busheufjyj (akyankppzz ) View more | Positive | 29 May 2020 | ||
hmjivjrfur(ezarshrrju) = wslwvuzrsa busheufjyj (akyankppzz ) View more | |||||||
Phase 3 | 4,089 | chemotherapy+trastuzumab (6-month) | zxxrsvcatq(aavikaqqdj) = poncdymtnt iybhirdejb (cshypcxhty ) View more | Positive | 29 Jun 2019 | ||
chemotherapy+trastuzumab (12-month) | zxxrsvcatq(aavikaqqdj) = ibcgnkrzcg iybhirdejb (cshypcxhty ) View more |